tiprankstipranks
Elevance Health, Inc. (ELV)
NYSE:ELV
Want to see ELV full AI Analyst Report?

Elevance Health (ELV) Price & Analysis

2,907 Followers

ELV Stock Chart & Stats

$323.05
<$0.01(<0.01%)
At close: 4:00 PM EST
$323.05
<$0.01(<0.01%)

Bulls Say, Bears Say

Bulls Say
Scale & Membership GrowthLarge, diversified membership across commercial, Medicare and Medicaid supports durable revenue scale and underwriting diversification. Steady membership and multi-year revenue growth create cost leverage, broader negotiating power with providers, and resilient premium inflows over a multi-quarter horizon.
Improved Cash GenerationA meaningful TTM free cash flow rebound and stronger operating cash flow underpin capital allocation flexibility. Consistent FCF coverage of earnings allows funding for buybacks, investments in Carelon/AI and potential regulatory payments while preserving liquidity across the next several quarters.
Carelon Clinical & Product TractionMeasured clinical outcomes and post-acute savings validate Carelon's integrated care model and support scalable third-party revenue. Demonstrable readmission and cost improvements strengthen competitive differentiation and position the services business to capture durable demand for value-based care.
Bears Say
CMS Risk-adjustment Accrual & Regulatory TimelineA sizable accrual and looming CMS compliance deadlines create regulatory and timing uncertainty that can materially affect cash flows and enrollment operations. Potential sanctions, remediation costs and ongoing oversight raise execution risk and could limit Medicare Advantage growth flexibility.
Medicaid Margin & Membership PressureSustained Medicaid membership declines and a negative operating margin expectation imply structural headwinds from eligibility reverifications and reimbursement dynamics. Persistent negative Medicaid profitability can weigh on consolidated margins and require cross-subsidization or pricing adjustments.
Balance-sheet Data InconsistencyAn unexplained sharp shift in reported total debt undermines transparency around leverage and liquidity. Even with equity growth and moderate leverage historically, such data discontinuities complicate capital planning and risk assessment for multi-quarter stress scenarios or large regulatory cash outflows.

Elevance Health News

ELV FAQ

What was Elevance Health, Inc.’s price range in the past 12 months?
Elevance Health, Inc. lowest stock price was $273.71 and its highest was $426.98 in the past 12 months.
    What is Elevance Health, Inc.’s market cap?
    Elevance Health, Inc.’s market cap is $84.37B.
      When is Elevance Health, Inc.’s upcoming earnings report date?
      Elevance Health, Inc.’s upcoming earnings report date is Jul 22, 2026 which is in 31 days.
        How were Elevance Health, Inc.’s earnings last quarter?
        Elevance Health, Inc. released its earnings results on Apr 22, 2026. The company reported $12.58 earnings per share for the quarter, beating the consensus estimate of $10.819 by $1.761.
          Is Elevance Health, Inc. overvalued?
          According to Wall Street analysts Elevance Health, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Elevance Health, Inc. pay dividends?
            Elevance Health, Inc. pays a Quarterly dividend of $1.72 which represents an annual dividend yield of 1.99%. See more information on Elevance Health, Inc. dividends here
              What is Elevance Health, Inc.’s EPS estimate?
              Elevance Health, Inc.’s EPS estimate is 6.2.
                How many shares outstanding does Elevance Health, Inc. have?
                Elevance Health, Inc. has 217,162,380 shares outstanding.
                  What happened to Elevance Health, Inc.’s price movement after its last earnings report?
                  Elevance Health, Inc. reported an EPS of $12.58 in its last earnings report, beating expectations of $10.819. Following the earnings report the stock price went up 0.027%.
                    Which hedge fund is a major shareholder of Elevance Health, Inc.?
                    Currently, no hedge funds are holding shares in ELV
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Elevance Health, Inc.

                      Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.

                      Elevance Health (ELV) Earnings & Revenues

                      ELV Company Deck

                      ELV Earnings Call

                      Q1 2026
                      0:00 / 0:00
                      Earnings Call Sentiment|Positive
                      The call emphasized strong execution and tangible operational improvements that drove a Q1 EPS beat, an upgraded full-year EPS guide, share repurchases and growing demand for integrated clinical and pharmacy offerings. Management also highlighted meaningful AI investments and measurable clinical results from Carelon/CareBridge (20% readmission reduction, >10% post-acute savings). Offsetting these positives are a material $935 million accrual related to a CMS historical risk-adjustment matter, a $129 million optimization charge, ongoing elevated Medicaid cost trends and some margin pressure and investment-driven cadence at Carelon. On balance the positives (guidance raise, underlying business beats, membership growth, cash generation and scalable AI/Carelon proof points) outweigh the negatives (one-time accrual, Medicaid pressure, Carelon margin timing), supporting a constructive outlook with manageable risks.View all ELV earnings summaries

                      ELV Stock 12 Month Forecast

                      Average Price Target

                      $414.79
                      ▲(28.40% Upside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"268":"$268","499":"$499","325.75":"$325.8","383.5":"$383.5","441.25":"$441.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":498,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$498.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":414.7894736842105,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$414.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":331,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$331.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[268,325.75,383.5,441.25,499],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.028,408.48738461538466,415.94676923076923,423.40615384615387,430.86553846153845,438.3249230769231,445.7843076923077,453.2436923076923,460.70307692307694,468.16246153846157,475.62184615384615,483.0812307692308,490.54061538461536,{"y":498,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.028,402.08657489878544,403.14514979757087,404.2037246963563,405.2622995951417,406.32087449392714,407.37944939271256,408.438024291498,409.4965991902834,410.5551740890688,411.61374898785425,412.6723238866397,413.7308987854251,{"y":414.7894736842105,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.028,395.6412307692308,390.25446153846156,384.8676923076923,379.4809230769231,374.09415384615386,368.7073846153846,363.3206153846154,357.93384615384616,352.54707692307693,347.1603076923077,341.77353846153846,336.38676923076923,{"y":331,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":367.671,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":387.617,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":269.009,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":312.094,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.593,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":312.369,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":324.659,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":346.99,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":338.358,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":291.083,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":297.29,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":371.169,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401.028,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Centene
                      CVS Health
                      Humana
                      Molina Healthcare
                      UnitedHealth

                      Ownership Overview

                      0.17%27.19%26.43%21.01%
                      26.43% Other Institutional Investors
                      21.01% Public Companies and Individual Investors
                      Popular Stocks